Vita 34 International : AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action

NOT FOR DISTRIBUTION, PUBLICATION OR DISCLOSURE IN OR WITHIN THE US, AUSTRALIA, JAPAN OR CANADA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION IS UNLAWFUL. PLEASE NOTE THE IMPORTANT NOTICES AT THE END OF THIS COMMUNICATION.

Vita 34 AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action

- Through MK Beleggingsmaatschappij Venlo B.V., Mr. Köhler takes over newly issued shares of up to 10% of the share capital

- Additional backstop agreed for just under EUR 3 million in connection with the upcoming rights issue

Leipzig, June 14, 2017 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe's second largest stem cell database, today announced the acquisition of a new strategic investor. Following the capital increase adopted yesterday, MK Beleggingsmaatschappij Venlo B.V., the Netherlands (MKBV), will hold approx. 9.1% of the share capital of Vita 34 and has also agreed to support Vita 34 in implementing its planned rights issue. To ensure the success of this rights issue, MKBV has assumed a backstop obligation according to which it will take over any unsubscribed new shares under this planned rights issue up to a maximum amount of just under EUR 3 million, provided the issue price does not exceed EUR 6.50. On April 20, 2017, Vita 34 AG had announced its plans to implement a capital increase including preemptive rights of existing shareholders to generate proceeds of up to EUR 5 million.

MKBV is the investment entity of Michael Köhler, CEO SHOP APOTHEKE Europe N.V., Venlo, Netherlands. Michael Köhler has more than 20 years experience in the pharmaceutical industry, including posts at Hoechst and Aventis. His investments focus on equity interests in medical technology and pharmaceutical companies. The investment in Vita 34 reflects the strategic potential shown by the stem cell therapy segment.

Michael Köhler, CEO of MK Beleggingsmaatschappij Venlo B.V., said: 'I believe Vita 34 has exciting growth potential in terms of business development and revenue as well as with regard to its market valuation. As Europe's second largest umbilical cord blood bank, Vita 34 has reached an interesting critical mass. For me, the takeover of Seracell therefore is the right strategic step. I am pleased to support the company in this endeavor.'

Dr. Wolfgang Knirsch, Chairman of the Management Board of Vita 34 AG, commented: 'We are delighted and proud to welcome MKBV and Mr. Köhler on board as a strategic anchor investor. His confidence in our work is due not least to his vast experience in the online and end customer business in the healthcare sector. We are convinced that his involvement and support at an early stage will enable us to successfully implement the rights issue that is currently being planned and to complete the takeover of Seracell Pharma AG as planned.'

Company profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. Some 160,000 families are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.

Important notice

This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities.

This publication may not be released, published or distributed in the United States of America, Australia, Japan or Canada. This publication neither constitutes an offer to sell nor an invitation to submit an offer to purchase or subscribe for securities (the 'Shares') in Vita 34 AG within the United States of America, Germany or any other state. Shares in Vita 34 AG may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the 'Securities Act'). Shares in Vita 34 AG are not and will not be registered in accordance with the provisions of the U.S. Securities Act.

As far as this document contains forward-looking statements these statements do not constitute facts and may be identified by words such as 'will', 'expect', 'believe', 'estimate', 'intend', 'aim', 'assume' or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of Vita 34 AG and persons acting in conjunction with Vita 34 AG. Any forward-looking statements contained in this document are based on current plans, estimates and projections which Vita 34 AG and persons acting in conjunction with Vita 34 AG have made to the best of their knowledge, but which do not claim to be correct in the future. Forward-looking statements are subject to risks and uncertainties that are difficult to predict and usually cannot be influenced by Vita 34 AG or persons acting in conjunction with Vita 34 AG. It should be kept in mind that the actual events or consequences may differ materially from those contained in or expressed by such forward-looking statements.

Related News

06/13/2017 Vita 34 AG decides on a capital increase of around 10%